All In MedTech

Device Trial Radar · NCT05757102

A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

A Phase 3, 24-week, Randomized, Double-blind, Parallel-group Bayesian Dynamic Borrowing Study Comparing the Efficacy, Safety, Tolerability and Pharmacokinetics of FF/UMEC/VI With FF/VI in 12-17-year-old Participants With Inadequately Controlled Asthma on Stable Maintenance Therapy With ICS/LABA

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 138 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

138

Planned (sponsor's estimate)

Start

Apr 24, 2023

Primary completion

Jan 26, 2027

Study completion Jan 28, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineNot on our public-company list
Sponsor type
Industry
First posted
Mar 7, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.

Conditions

  • Asthma

Interventions

  • FF/UMEC/VIDrug

    FF/UMEC/VI will be administered.

  • ELLIPTADevice

    FF/UMEC/VI and FF/VI will be administered via ELLIPTA inhaler

  • FF/VIDrug

    FF/VI will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in trough forced expiratory volume in 1 second (FEV1) (Liters) at Week 24Time frame: Baseline (Week 0) and Week 24

Locations

67 sites in 9 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Mobile, Alabama

  • GSK Investigational Site

    Paradise Valley, Arizona

64 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.